Research Article

microRNA-203 and predicts 2-year restenosis risk in coronary heart disease patients

Department of Cardiology, People's Hospital of Mudan, Heze, PR China

‡Authors contributed equally to this work

Search for more papers by this author

Yinchuan Zhu‡

Department of Vasculocardiology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR. China

‡Authors contributed equally to this work

Search for more papers by this author

Yingchao Liu

Department of Clinical Laboratory, The Second People's Hospital of Liaocheng, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, Linqing, PR China

Search for more papers by this author

Yanru Liu

Department of Cardiology, People's Hospital of Mudan, Heze, PR China

Search for more papers by this author

Xiaoyu Chen

*Author for correspondence: Tel.: +86 053 0551 5012;

E-mail Address: yutaoshan7747@126.com

https://orcid.org/0000-0002-9913-4898

Department of Clinical Laboratory, People's Hospital of Mudan, Heze, PR China

Search for more papers by this author

Published Online:10 Feb 2021https://doi.org/10.2217/bmm-2020-0715

View article

Abstract

Aim: To investigate correlations of long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (lnc-MALAT1) and its target microRNAs with clinical features and restenosis risk in coronary heart disease (CHD) patients post drug-eluting stent-percutaneous coronary intervention (DES-PCI). Materials & methods: A total of 274 CHD patients undergoing DES-PCI were enrolled, pre-operative plasma samples were obtained to detect lnc-MALAT1, miR-125b, miR-146a, miR-203 by RT-qPCR; 2-year restenosis was determined by quantitative coronary angiography. Results: Lnc-MALAT1 negatively correlated with miR-125b, miR-146a and miR-203. Furthermore, lnc-MALAT1, miR-125b, miR-146a and miR-203 correlated with diabetes mellitus, hyperuricemia, lesion properties, cholesterol, inflammation and cardiac function indexes. Additionally, lnc-MALAT1 was increased, while miR-125b and miR-146a were decreased in patients with 2-year restenosis than patients without 2-year restenosis; however, miR-203 did not differ. Conclusion: Lnc-MALAT1 and its target miRNAs might help manage restenosis risk in CHD patients post DES-PCI.

Keywords:

References

1. Figulla HR, Lauten A, Maier LS, Sechtem U, Silber S, Thiele H. Percutaneous coronary intervention in stable coronary heart disease: is less more? Dtsch. Arztebl. Int. 117(9), 137–144 (2020).
MedlineGoogle Scholar
2. Cagle SD Jr, Cooperstein N. Coronary artery disease: diagnosis and management. Prim. Care 45(1), 45–61 (2018).
MedlineGoogle Scholar
3. Simoons ML, Windecker S. Controversies in cardiovascular medicine: chronic stable coronary artery disease: drugs vs. revascularization. Eur. Heart J. 31(5), 530–541 (2010).
MedlineGoogle Scholar
4. Xiu WJ, Yang HT, Zheng YY, Ma YT, Xie X. Drug-eluting balloons versus second-generation drug-eluting stents for treating in-stent restenosis in coronary heart disease after pci: a meta-analysis. Cardiol. Res. Pract. 2018, 7658145 (2018).
MedlineGoogle Scholar
5. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 373(9667), 911–918 (2009).
MedlineGoogle Scholar
6. Zhu Y, Yang T, Duan J, Mu N, Zhang T. MALAT1/miR-15b-5p/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway. Aging (Albany NY) 11(4), 1089–1109 (2019).
Medline CASGoogle Scholar
7. Arun G, Aggarwal D, Spector DL. MALAT1 long non-coding RNA: functional implications. Noncoding RNA 6(2), 22 (2020).
CASGoogle Scholar
8. Yan Y, Song D, Song X, Song C. The role of lncRNA MALAT1 in cardiovascular disease. IUBMB Life 72(3), 334–342 (2020).
Medline CASGoogle Scholar
9. Wang L, Qi Y, Wang Y et al. LncRNA MALAT1 suppression protects endothelium against oxLDL-induced inflammation via inhibiting expression of MiR-181b target gene TOX. Oxid. Med. Cell Longev. 2019, 8245810 (2019).
MedlineGoogle Scholar
10. Huangfu N, Xu Z, Zheng W, Wang Y, Cheng J, Chen X. LncRNA MALAT1 regulates oxLDL-induced CD36 expression via activating beta-catenin. Biochem. Biophys. Res. Commun. 495(3), 2111–2117 (2018).
MedlineGoogle Scholar
11. Song Y, Yang L, Guo R, Lu N, Shi Y, Wang X. Long noncoding RNA MALAT1 promotes high glucose-induced human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22. Biochem. Biophys. Res. Commun. 509(2), 359–366 (2019).
Medline CASGoogle Scholar
12. Dai L, Zhang G, Cheng Z et al. Knockdown of LncRNA MALAT1 contributes to the suppression of inflammatory responses by up-regulating miR-146a in LPS-induced acute lung injury. Connect Tissue Res. 59(6), 581–592 (2018).
Medline CASGoogle Scholar
13. Chen H, Wang X, Yan X, Cheng X, He X, Zheng W. LncRNA MALAT1 regulates sepsis-induced cardiac inflammation and dysfunction via interaction with miR-125b and p38 MAPK/NFkappaB. Int. Immunopharmacol. 55, 69–76 (2018).
Medline CASGoogle Scholar
14. Wang S, Yu W, Chen J, Yao T, Deng F. LncRNA MALAT1 sponges miR-203 to promote inflammation in myocardial ischemia-reperfusion injury. Int. J. Cardiol. 268, 245 (2018).
MedlineGoogle Scholar
15. Li X, Yao N, Zhang J, Liu Z. MicroRNA-125b is involved in atherosclerosis obliterans in vitro by targeting podocalyxin. Mol. Med. Rep. 12(1), 561–568 (2015).
Medline CASGoogle Scholar
16. Xiao Q, Zhu X, Yang S et al. LPS induces CXCL16 expression in HUVECs through the miR-146a-mediated TLR4 pathway. Int. Immunopharmacol. 69, 143–149 (2019).
Medline CASGoogle Scholar
17. Zhang J, Pan J, Yang M et al. Upregulating microRNA-203 alleviates myocardial remodeling and cell apoptosis through downregulating protein tyrosine phosphatase 1B in rats with myocardial infarction. J. Cardiovasc. Pharmacol. 74(5), 474–481 (2019).
Medline CASGoogle Scholar
18. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc. Interv. 4(10), 1057–1066 (2011).
MedlineGoogle Scholar
19. Qiu S, Sun J. lncRNA-MALAT1 expression in patients with coronary atherosclerosis and its predictive value for in-stent restenosis. Exp. Ther. Med. 20(6), 129 (2020).
Medline CASGoogle Scholar
20. Zhang H, Zhang Q, Liu Y, Xue T. miR-146a and miR-146b predict increased restenosis and rapid angiographic stenotic progression risk in coronary heart disease patients who underwent percutaneous coronary intervention. Ir. J. Med. Sci. 189(2), 467–474 (2020).
Medline CASGoogle Scholar
21. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter. Cardiovasc. Interv. 82(4), E266–355 (2013).
MedlineGoogle Scholar
22. Liu S, Liu M, Dong L. The clinical value of lncRNA MALAT1 and its targets miR-125b, miR-133, miR-146a, and miR-203 for predicting disease progression in chronic obstructive pulmonary disease patients. J. Clin. Lab. Anal. doi:10.1002/jcla.23410 34(9), e23410 (2020).
Medline CASGoogle Scholar
23. Bruining N, Sabate M, De Feyter PJ et al. Quantitative measurements of in-stent restenosis: a comparison between quantitative coronary ultrasound and quantitative coronary angiography. Catheter. Cardiovasc. Interv. 48(2), 133–142 (1999).
Medline CASGoogle Scholar
24. Haase J, Escaned J, Van Swijndregt EM et al. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet. Cardiovasc. Diagn. 30(2), 104–114 (1993).
Medline CASGoogle Scholar
25. Gronenschild E, Janssen J, Tijdens F. CAAS. II: a second generation system for off-line and on-line quantitative coronary angiography. Cathet. Cardiovasc. Diagn. 33(1), 61–75 (1994).
Medline CASGoogle Scholar
26. Serruys PW, Foley DP, Feyter PJD. Quantitative Coronary Angiography in Clinical Practice. Springer, The Netherlands (1994).
Google Scholar
27. Wu Y, Fu X. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation. J. Clin. Lab. Anal. 33(2), e22666 (2019).
MedlineGoogle Scholar
28. Toraih EA, El-Wazir A, Alghamdi SA et al. Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events. Genet Mol. Biol. 42(3), 509–518 (2019).
Medline CASGoogle Scholar
29. Cheng Y, Li J, Wang C et al. Inhibition of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 attenuates high glucose-induced cardiomyocyte apoptosis via regulation of miR-181a-5p. Exp. Anim. 69(1), 34–44 (2020).
Medline CASGoogle Scholar
30. Ding H, Wang F, Shi X et al. LncRNA MALAT1 induces the dysfunction of beta cells via reducing the histone acetylation of the PDX-1 promoter in Type 1 diabetes. Exp. Mol. Pathol. 114, 104432 (2020).
Medline CASGoogle Scholar
31. Yu CY, Yang CY, Rui ZL. MicroRNA-125b-5p improves pancreatic beta-cell function through inhibiting JNK signaling pathway by targeting DACT1 in mice with Type 2 diabetes mellitus. Life Sci. 224, 67–75 (2019).
Medline CASGoogle Scholar
32. Feng B, Chen S, McArthur K et al. miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 60(11), 2975–2984 (2011).
Medline CASGoogle Scholar
33. Nesca V, Guay C, Jacovetti C et al. Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of Type 2 diabetes. Diabetologia 56(10), 2203–2212 (2013).
Medline CASGoogle Scholar
34. Li K, Zhao B, Wei D et al. miR146a improves hepatic lipid and glucose metabolism by targeting MED1. Int. J. Mol. Med. 45(2), 543–555 (2020).
Medline CASGoogle Scholar
35. Cheng XY, Liu JD, Lu XY et al. miR-203 Inhibits alcohol-induced hepatic steatosis by targeting lipin1. Front Pharmacol. 9, 275 (2018).
MedlineGoogle Scholar
36. Sud N, Zhang H, Pan K, Cheng X, Cui J, Su Q. Aberrant expression of microRNA induced by high-fructose diet: implications in the pathogenesis of hyperlipidemia and hepatic insulin resistance. J. Nutr. Biochem. 43, 125–131 (2017).
Medline CASGoogle Scholar
37. Nassirpour R, Mathur S, Gosink MM et al. Identification of tubular injury microRNA biomarkers in urine: comparison of next-generation sequencing and qPCR-based profiling platforms. BMC Genomics 15, 485 (2014).
MedlineGoogle Scholar

Vol. 15, No. 4

Supplemental Materials

Metrics

Downloaded 119 times

History

Received 23 October 2020

Accepted 22 December 2020

Published online 10 February 2021

Published in print March 2021

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/bmm-2020-0715

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

All patients provided the written informed consents, and this study was approved by the Institutional Review Board of the hospital.

Data availability

The datasets used and/or analyses during the current study are available from the corresponding author on reasonable request.

PDF download